Compare DexCom, Inc. (DXCM) vs TJX Companies Inc (TJX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs TJX Companies Inc — how do they compare? DexCom, Inc. trades at $90.8 (market cap $33.79B), while TJX Companies Inc trades at $153.51 (market cap $172.05B). The key difference: TJX Companies Inc is far larger — about 5.1× DexCom, Inc.'s market cap, and TJX Companies Inc pays a 1.23% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| DXCM | TJX | |
|---|---|---|
Market Cap | $33.79B | $172.05B |
Sector | Health | Consumer Cyclical |
52-Week High | $89.53 | $168.41 |
52-Week Low | $54.84 | $132.62 |
Enterprise Value | $33.24B | $180.65B |
Dividend Yield | — | 1.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $91.00, up 3.82% today and near its 52-week high, with bullish technical signals from moving averages and strong fundamentals. Recent Q2 2026 earnings beat expectations with EPS of $0.70 versus $0.61 expected, driven by 13% revenue growth and margin expansion. The company raised full-year 2026 guidance, reflecting robust demand for continuous glucose monitors.
The outlook is positive due to sustained revenue growth, profitability improvements, and analyst consensus favoring buys. Risks include competitive pressures and potential regulatory scrutiny, but institutional ownership trends and earnings momentum support a constructive view for investors seeking exposure to medical technology.
TJX trades at $152.64, down 3.88% in the last session, with a bearish technical signal but strong fundamentals including a 61.25% ROE and consistent earnings beats. Revenue grew to $56.36B in 2025, with net income margin expanding to 8.63%. The company maintains robust cash flow from operations at $6.12B and announced dividends of $0.48 per share for H1 and H2 2026.
Outlook remains positive with analyst consensus price target of $181.80 (19% upside), supported by 88% buy ratings. Risks include competitive discount retail pressures and macroeconomic sensitivity, but TJX's value proposition and growth trajectory offer investment opportunity pending Q2 2026 earnings on August 19, 2026.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About TJX Companies Inc
TJX is a leading off-price retailer of apparel, home fashions, and other merchandise. It sells a variety of branded goods, opportunistically buying inventory from a network of over 21,000 vendors worldwide. TJX targets undercutting conventional retailers' regular prices by 20%-60%, capitalizing on a flexible merchandising network, relatively low-frills stores, and a treasure-hunt shopping experience to drive margins and inventory turnover. TJX derived 79% of fiscal 2022 revenue from the United States, with 11% from Europe (mostly the United Kingdom and Germany), 9% from Canada, and the remainder from Australia. The company operated 4,689 stores at the end of fiscal 2022 under the T.J. Maxx, T.K. Maxx, Marshalls, HomeGoods, Winners, Homesense, Winners, and Sierra banners.
Read more on TJX →
